Connect with us

Cancer

The fight against cancer is ongoing: #WorldCancerDay and the EU’s broader health-care issues

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

Most of us know, have known, or will know someone with cancer. It is perhaps the most singular threat to health care on a worldwide scale, despite all the incredible leaps lately in diagnosis and treatment, writes European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan.

Now the annually held World Cancer Day (4 February) is upon us, and tomorrow will see global events under the current three-year theme I Am And I Will.

The day serves to recognize that a commitment by all those able to act will lead to powerful progress in reducing the global impact of cancer, and all actions - big and small - can make lasting, positive change.

World Cancer Day and ongoing campaigns are built to resonate, inspire change and mobilize action long after the day has passed, and the organizers believe, as does EAPM that a multi-year campaign offers a chance to create long-lasting impact by increasing public-facing exposure and engagement, more opportunities to build global awareness and impact-driven action.

2020 marks the midway point of the aforementioned three-year I Am and I Will’ campaign, which represents an empowering call-to-action urging personal commitment and represents the power of action taken now to have a positive impact on the future.

European initiatives

This year is an especially important one in the sphere of cancer for EU citizens, given the Ursula von der Leyen Commission’s Beating Cancer Plan, which the European Alliance for Personalised Medicine supports wholeheartedly.

Advertisement

Essentially, the European Commission has pledged to make the battle against cancer in Europe a key priority of the legislative term. 

EAPM is also playing its part, not least in the form of three upcoming Presidency conferences which will help to underline the need for urgent action.  

All politicians and stakeholders working in health care know how high citizens place health and health care on the day-to-day agenda, but we need concrete actions right now to go with the well-meaning talk and pledges for the future.

Patients need action, citizens need it and, put bluntly in this ‘cash is king’ world, the economy needs it. 

Among the key questions in healthcare in general and cancer in particular is how do we bring innovation into health-care systems so that we can have earlier diagnosis and a better quality of life for citizens?

EAPM and its stakeholders and partners know that and also that we need better use of health data, a well-trained workforce up to date with new methods, and an educated citizenry that understands (and as a result takes at least some responsibility for) its own health needs.

On top of this, and where EAPM is especially effective, we need a progressive, workable and sustainable governance framework which, among other key elements, takes into account genomics, data and access to high quality testing. In this personalised medicine world, we need to know which disease a patient has as well as an individual’s predisposition to a disease for preventative purposes.

Getting this right will ensure better healthcare for citizens and go a long way to upholding the EU’s aims of a high-quality way of life.

Everyone has a role to play via a multistakeholder approach, much-championed by EAPM and its colleagues.  

The Alliance has fully supported the proposal for Cancer Missions, has worked hard to promote lung-cancer and prostate screening andmore recently, has put its weight behind the MEGA+ initiative that aims to increase the exchange of all valuable health-related data.

Alongside all this, the underlying goal has been to put, and keep, the person in personalised healthcare.

All stakeholders, member state-governments, communities, employers and media have a role to play to challenge perceptions about cancer to create a culture and a population where people living with the disease do not face discrimination in the workplace, in the health system or in our society.

Meanwhile, access to the best treatment available for all citizens is one of the tenets of personalised medicine, and making this happen is a moral imperative supported by all of us at EAPM and every stakeholder in this arena.

(To view our current programme of our March 24th Conference on Personalised Medicine, please click here and to register your attendance, please click here.)

Drawing the battle lines

So while we have used this opportunity to highlight World Cancer Day, the fight must go on during every one of the other 364 days of every single year.

Because, make no mistake, it is a fight. A true battle often against ridiculous odds. For example, in the now-departed UK, research has shown that cancer medicines are taking longer to get to patients in the NHS. The timeline from patent priority to patient availability increased from 12.8 years to 14 years between 2009-2016.

Meanwhile, in certain cancer areas, no new drugs are being licensed for use. This is an unacceptable situation, anywhere, in the third decade of the 21st century.

Moving forward - EU values and ‘way of life’

The Commission’s just-released work programme sets out the most important initiatives the EU Executive intends to take in its first year, and will act as a foundation for actions.

It is focused around the six headline ambitions set out in President von der Leyens Political Guidelines, and also reflects the main priorities for the European Parliament and those in the European Councils Strategic Agenda for 2019-2024.

As the Commission puts it: “The European way of life is built around our values of solidarity, equality and fairness. It is about feeling safe, secure and having peace of mind, supporting the most vulnerable in our society and championing inclusion. 

It is about finding common solutions to shared challenges and equipping people with the skills they need, and investing in their health and wellbeing. It is about building stronger, more cohesive and more resilient European societies.

The Work Programme acknowledges also that the EU “has an important role in helping Europeans take care of their health. We want Europe to take the lead in the fight against cancer”. 

It explains that the Commission will put forward Europes Beating Cancer Plan to support member states in their efforts to improve cancer prevention and care. The Commission will also launch a Pharmaceutical Strategy for Europe to continue ensuring the quality and safety of medicines and consolidating the sector’s global competitiveness. 

Europe should also make sure that all patients can benefit from innovation while resisting the pressure of increasing costs of medicines, the programme states, while focusing also on education.

Looking ahead, the Commission says it will present a Report on the Impact of Demographic Change, which will look at how new demographic realities affect everything from social and regional policy, health, finance, digital connectivity, skills and integration. 

The Commission will also propose a long-term vision for rural areas and a Green Paper on Ageing, a key issue in modern-day health care.

And so, farewell, then…

Health and many other issues know no borders, and the UK’s departure from the EU late last Friday marks the beginning of months of tough negotiations over the vital future relationship, set against yet another deadline - this one 31 December, after which UK Prime Minister Boris Johnson says there will be no more talks.

Discussions will certainly start and without doubt intensify on trade, immigration and financial services, as well as on medicines and health care.

The coronavirus that has emerged from China and is spreading globally has already shown that research partnerships between the EU and Britain need to be kept working well.

On top of this, the Association of European Cancer Leagues has sent out a letter to Europes health ministers, their health attachés and the EUs negotiating team to try to make sure that any future relationship won’t leave cancer patients behind. 

This means, among other elements, cross-border trials continuing, plus access to all necessary cancer drugs and medical devices being maintained. (The European Pharmaceutical Review says that almost 90% of UK pharmacists are concerned about the supply of medicines after Brexit.)

Meanwhile, the European Medical Organisations have also called on EU-UK negotiators to do whatever is necessary” to ensure that the European medical profession can continue to treat its patients to the highest possible level beyond the end of the transition period”. Not just in cancer, but across the healthcare spectrum.

There’s much to be done, but the Commission is certainly striving to make inroads. And you can be assured that EAPM will remain in the vanguard as we move forward in our bid to put people at the centre of modern medicine and deliver the access to the care that they need, deserve and have been promised.

(To view our current programme of our March 24th Conference on Personalised Medicine, please click here and to register your attendance, please click here.)

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.

Trending